Literature DB >> 15135058

Furin cleavage of the HIV-1 Tat protein.

Ilia Tikhonov1, Tracy J Ruckwardt, Shannon Berg, Glen S Hatfield, C David Pauza.   

Abstract

Extracellular human immunodeficiency virus-1 (HIV-1) Tat protein and Tat-derived peptides are biologically active but mechanisms of Tat processing are not known. Within the highly conserved basic region of HIV-1 Tat protein (amino acids, a.a. 48-56), we identified two putative furin cleavage sites and showed that Tat protein was cleaved in vitro at the second site, RQRR\ (a.a. 53-56\). This in vitro cleavage was blocked by a monoclonal antibody that binds near the cleavage site or by the furin inhibitor alpha-1 PDX. Monocytoid cells rich in furin also degraded Tat and this process was slowed by the furin inhibitor or the specific monoclonal antibody. Furin processing did not affect the rates for Tat uptake and nuclear accumulation in HeLa or Jurkat cells, but the transactivation activity was greatly reduced. Furin processing is a likely mechanism for inactivating extracellular HIV-1 Tat protein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135058     DOI: 10.1016/j.febslet.2004.03.079

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

Review 1.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

2.  Expressed cell-penetrating peptides can induce a bystander effect, but passage through the secretory pathway reduces protein transduction activity.

Authors:  Ying Shen; William Yu; John G Hay; Harald Sauthoff
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

Review 3.  The taming of the cell penetrating domain of the HIV Tat: myths and realities.

Authors:  Ashok Chauhan; Akshay Tikoo; Arvinder K Kapur; Mahavir Singh
Journal:  J Control Release       Date:  2006-11-17       Impact factor: 9.776

4.  PKA-type I selective constrained peptide disruptors of AKAP complexes.

Authors:  Yuxiao Wang; Tienhuei G Ho; Eugen Franz; Jennifer S Hermann; F Donelson Smith; Heidi Hehnly; Jessica L Esseltine; Laura E Hanold; Mandi M Murph; Daniela Bertinetti; John D Scott; Friedrich W Herberg; Eileen J Kennedy
Journal:  ACS Chem Biol       Date:  2015-03-25       Impact factor: 5.100

5.  TAT peptide and its conjugates: proteolytic stability.

Authors:  Jacob Grunwald; Tomas Rejtar; Rupa Sawant; Zhouxi Wang; Vladimir P Torchilin
Journal:  Bioconjug Chem       Date:  2009-07-14       Impact factor: 4.774

6.  Delivery of therapeutic proteins as secretable TAT fusion products.

Authors:  Marcella Flinterman; Farzin Farzaneh; Nagy Habib; Farooq Malik; Joop Gäken; Mahvash Tavassoli
Journal:  Mol Ther       Date:  2008-12-02       Impact factor: 11.454

7.  Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases.

Authors:  Yong Xiao; Gang Chen; Jonathan Richard; Nicole Rougeau; Hongshan Li; Nabil G Seidah; Eric A Cohen
Journal:  Virology       Date:  2007-12-03       Impact factor: 3.616

8.  A study of human furin specificity using synthetic peptides derived from natural substrates, and effects of potassium ions.

Authors:  Mario A Izidoro; Iuri E Gouvea; Jorge A N Santos; Diego M Assis; Vitor Oliveira; Wagner A S Judice; Maria A Juliano; Iris Lindberg; Luiz Juliano
Journal:  Arch Biochem Biophys       Date:  2009-05-27       Impact factor: 4.013

9.  HIV-1 Tat C-terminus is cleaved by calpain 1: implication for Tat-mediated neurotoxicity.

Authors:  Giovanni Passiatore; Slava Rom; Davide Eletto; Francesca Peruzzi
Journal:  Biochim Biophys Acta       Date:  2008-10-31

10.  Secretory TAT-peptide-mediated protein transduction of LIF receptor α-chain distal cytoplasmic motifs into human myeloid HL-60 cells.

Authors:  Q Sun; J Xiong; J Lu; S Xu; Y Li; X P Zhong; G K Gao; H Q Liu
Journal:  Braz J Med Biol Res       Date:  2012-06-21       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.